Literature DB >> 6982086

Acquired amegakaryocytic thrombocytopenic purpura: a syndrome of diverse etiologies.

R Hoffman, E Bruno, J Elwell, E Mazur, A M Gewirtz, P Dekker, A E Denes.   

Abstract

The possible pathogenetic mechanisms responsible for the production of acquired amegakaryocytic thrombocytopenic purpura (AATP) were investigated in a group of patients with this disorder. Absence of megakaryocytes and small platelet glycoprotein-bearing mononuclear cells, as determined by immunochemical staining of patient marrows with an antisera to platelet glycoproteins, suggested that the defect in AATP occurs in an early progenitor cell of the megakaryocytic lineage. Using an in vitro clonal assay system for negakaryocytic progenitor cells or megakaryocyte colony-forming units (CFU-M), the proliferative capacity of AATP marrow cells was then assessed. Bone marrow cells from three of four patients formed virtually no megakaryocyte colonies, suggesting that in these individuals the AATP was due to an intrinsic defect in the CFU-M. Bone marrow cells from an additional patient, however, formed 12% of the normal numbers of colonies, providing evidence for at least partial integrity of the CFU-M compartment in this patient. Serum specimens from all six patients were screened for their capacity to alter in vitro megakaryocyte colony formation. Five of six sera enhanced colony formation in a stepwise fashion, demonstrating appropriately elevated levels of megakaryocyte colony-stimulating activity. The serum of the patient with partial integrity of the CFU-M compartment, however, stimulated colony formation only at low concentrations. At higher concentrations, this patient's serum actually inhibited the number of colonies cloned, suggesting the presence of a humoral inhibitor to CFU-M. Serum samples from all patients were further screened for such humoral inhibitors of megakaryocyte colony formation using a cytotoxicity assay. The patient whose serum was inhibitory to CFU-M at high concentrations was indeed found to have a complement-dependent serum IgG inhibitor that was cytotoxic to allogeneic and autologous marrow CFU-M but did not alter erythroid colony formation. These-studies suggest that AATP can be due to at least two mechanisms: either an intrinsic effect at the level of the CFU-M or a circulating cytotoxic autoantibody directed against the CFU-M.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6982086

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Acquired amegakaryocytic thrombocytopenia purpura in a Rhesus macaque (Macaca mulatta).

Authors:  Patrick W Hanley; Wallace B Baze; Mark J McArthur; Bruce J Bernacky; Greg K Wilkerson; Kirstin F Barnhart
Journal:  Comp Med       Date:  2012-06       Impact factor: 0.982

2.  Mononeuritis multiplex in acquired amegakaryocytic thrombocytopenia.

Authors:  Firosh Khan; Abdulkhader Shehna; Lekha Mukundan
Journal:  J Neurosci Rural Pract       Date:  2015 Oct-Dec

3.  Are mild/moderate acquired idiopathic aplastic anaemia and low-risk myelodysplastic syndrome one or two diseases or both and how should it/they be treated?

Authors:  S Nakao; R P Gale
Journal:  Leukemia       Date:  2016-09-02       Impact factor: 11.528

4.  Successful treatment of acquired amegakaryocytic thrombocytopenic purpura refractory to corticosteroids and intravenous immunoglobulin with antithymocyte globulin and cyclosporin.

Authors:  Pimjai Niparuck; Vichai Atichartakarn; Suporn Chuncharunee
Journal:  Int J Hematol       Date:  2008-07-15       Impact factor: 2.490

5.  Danazol in acquired amegakaryocytic thrombocytopenic purpura: a case report.

Authors:  W Kayser; H H Euler; N Schmitz; W Gassmann; H Löffler; F Asbeck
Journal:  Blut       Date:  1985-12

6.  Purification and partial characterization of a megakaryocyte colony-stimulating factor from human plasma.

Authors:  R Hoffman; H H Yang; E Bruno; J E Straneva
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

7.  Human megakaryocytic progenitor cells.

Authors:  L Kanz; G W Löhr; A A Fauser
Journal:  Klin Wochenschr       Date:  1987-04-01

8.  Acquired Amegakaryocytic Thrombocytopenia Misdiagnosed as Immune Thrombocytopenia: A Case Report.

Authors:  Arya Mariam Roy; Manojna Konda; George K Sidarous; Dinesh Atwal; Steven A Schichman; Anuradha Kunthur
Journal:  Perm J       Date:  2020-12

9.  Long-term outcome of isolated thrombocytopenia accompanied by hypocellular marrow.

Authors:  Gak-Won Yun; Young-Jun Yang; Ik-Chan Song; Seung-Woo Baek; Kyu-Seop Lee; Hyo-Jin Lee; Hwan-Jung Yun; Kye-Chul Kwon; Samyong Kim; Deog-Yeon Jo
Journal:  Korean J Hematol       Date:  2011-06-21

10.  Danazol: an effective option in acquired amegakaryocytic thrombocytopaenic purpura.

Authors:  E Mulroy; S Gleeson; S Chiruka
Journal:  Case Rep Hematol       Date:  2015-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.